OK, maybe this angle will clarify it better than my first two posts did: Pharmas partner by geography all the time. If you have rights in the US, you have it for whatever indications you choose to pursue. CX-516 was sliced up by indication, with Servier having worldwide control over neurodegeneration. A company partnering with Cortex in North America could only develop CX-516 for indications other than Alzheimer's, Parkinson's, Huntington's, and could have been faced with another company trying to sell the same drug in the same territory, but possibly for a different price. That is not what this current scenario would produce.
NeuroInvestment
Market Data 
Markets 
AI
